GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.67 USD
-0.49 (-1.25%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $38.68 +0.01 (0.03%) 5:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.67 USD
-0.49 (-1.25%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $38.68 +0.01 (0.03%) 5:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
GlaxoSmithKline (GSK) Stock Moves -1.71%: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $44.92, moving -1.71% from the previous trading session.
Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges
by Zacks Equity Research
Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.25, marking a -1.07% move from the previous day.
Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
by Zacks Equity Research
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
by Zacks Equity Research
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.10, marking a +0.49% move from the previous day.
Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE
by Kinjel Shah
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.
J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $44.88, moving -1.77% from the previous trading session.
Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer
by Zacks Equity Research
Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.
Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business
by Zacks Equity Research
Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.
The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo
by Zacks Equity Research
Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.
Glaxo (GSK), Vir Seek EUA for Intramuscular Sotrovimab in US
by Zacks Equity Research
Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.
Pharma Stock Roundup: PFE's Research Deal With BEAM & Other Updates
by Kinjel Shah
Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancer
GlaxoSmithKline (GSK) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.06, marking a -0.4% move from the previous day.
Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US
by Zacks Equity Research
The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $45.04 in the latest trading session, marking a +0.45% move from the prior day.
Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $43.60 in the latest trading session, marking a +0.14% move from the prior day.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $43.54 in the latest trading session, marking a -0.3% move from the prior day.
Spero (SPRO) Application for UTI Drug Gets Priority Review
by Zacks Equity Research
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug
by Zacks Equity Research
Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.
Jazz (JAZZ) Enrolls First Patient in Psychiatric Disorder Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase II study to evaluate JZP150 for treating adults with post-traumatic stress disorder.